Neovasc Stock Forecast, Price & News

-0.02 (-1.84 %)
(As of 06/24/2021 12:12 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,055 shs
Average Volume3.73 million shs
Market Capitalization$60.76 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVCN News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

Neovasc logo

About Neovasc

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

748th out of 2,105 stocks

Surgical & Medical Instruments Industry

65th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Neovasc (NASDAQ:NVCN) Frequently Asked Questions

Is Neovasc a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc
or view top-rated stocks.

What stocks does MarketBeat like better than Neovasc?

Wall Street analysts have given Neovasc a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neovasc wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neovasc?

Neovasc saw a decline in short interest in May. As of May 28th, there was short interest totaling 1,780,000 shares, a decline of 24.6% from the May 13th total of 2,360,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.8% of the shares of the company are sold short.
View Neovasc's Short Interest

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Neovasc

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) posted its earnings results on Thursday, May, 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.06. The medical equipment provider earned $0.45 million during the quarter, compared to analysts' expectations of $0.60 million. Neovasc had a negative trailing twelve-month return on equity of 157.95% and a negative net margin of 1,425.96%.
View Neovasc's earnings history

How has Neovasc's stock been impacted by COVID-19 (Coronavirus)?

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVCN shares have decreased by 59.3% and is now trading at $0.9001.
View which stocks have been most impacted by COVID-19

When did Neovasc's stock split? How did Neovasc's stock split work?

Neovasc shares reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

What price target have analysts set for NVCN?

2 brokerages have issued 1 year price targets for Neovasc's shares. Their forecasts range from $2.00 to $5.00. On average, they expect Neovasc's stock price to reach $3.50 in the next year. This suggests a possible upside of 288.8% from the stock's current price.
View analysts' price targets for Neovasc
or view top-rated stocks among Wall Street analysts.

Who are Neovasc's key executives?

Neovasc's management team includes the following people:
  • Mr. Fredericus A. Colen, Pres, CEO & Director (Age 68, Pay $664.97k)
  • Mr. Christopher Clark B.A., C.A., BA (Honours), PgD, CA, CFO & Corp. Sec. (Age 49, Pay $400.46k)
  • Mr. William Reed Little, Chief Operating Officer (Age 49, Pay $452.25k)
  • Mr. John Christopher Panton, Chief Quality Officer (Age 54, Pay $238.22k)

Who are some of Neovasc's key competitors?

What other stocks do shareholders of Neovasc own?

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Who are Neovasc's major shareholders?

Neovasc's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.66%), GenTrust LLC (0.59%), Ameraudi Asset Management Inc. (0.59%), Royal Bank of Canada (0.14%), Citadel Advisors LLC (0.11%) and Citadel Advisors LLC (0.11%).

Which institutional investors are buying Neovasc stock?

NVCN stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GenTrust LLC, Ameraudi Asset Management Inc., Royal Bank of Canada, Citadel Advisors LLC, and Citadel Advisors LLC.

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $0.90.

How much money does Neovasc make?

Neovasc has a market capitalization of $60.76 million and generates $1.96 million in revenue each year. The medical equipment provider earns $-28,690,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Neovasc have?

Neovasc employs 71 workers across the globe.

What is Neovasc's official website?

The official website for Neovasc is

Where are Neovasc's headquarters?

Neovasc is headquartered at Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at (604) 270-4344 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.